Nations Financial Group Inc. IA ADV Purchases 4,956 Shares of AbbVie Inc. $ABBV

Nations Financial Group Inc. IA ADV grew its position in shares of AbbVie Inc. (NYSE:ABBV) by 30.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,376 shares of the company’s stock after buying an additional 4,956 shares during the period. Nations Financial Group Inc. IA ADV’s holdings in AbbVie were worth $4,884,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in AbbVie by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after buying an additional 448,554 shares during the period. Legal & General Group Plc increased its position in AbbVie by 4.3% during the 3rd quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock worth $2,779,426,000 after buying an additional 493,420 shares during the period. Wellington Management Group LLP increased its position in AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after buying an additional 8,646,424 shares during the period. Amundi increased its position in AbbVie by 15.6% during the 3rd quarter. Amundi now owns 10,508,317 shares of the company’s stock worth $2,418,909,000 after buying an additional 1,414,621 shares during the period. Finally, Ameriprise Financial Inc. increased its position in AbbVie by 4.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company’s stock worth $2,241,363,000 after buying an additional 408,426 shares during the period. Institutional investors own 70.23% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Late?breaking Phase 2 data for mirvetuximab (Elahere) in platinum?sensitive ovarian cancer and an exclusive pain?therapy licensing deal reinforce AbbVie’s longer?term oncology and pain pipelines, supporting growth expectations. AbbVie Ovarian Cancer Data And Pain Deal Extend Long Term Story
• Positive Sentiment: AbbVie paid a reported upfront to secure global rights to RC148, signaling management is investing in external oncology/R&D assets to bolster future revenue streams and diversify the pipeline. RemeGen Receives US$650 Million Upfront from AbbVie for RC148 Global Rights
• Positive Sentiment: AbbVie reached a large licensing agreement with Haisco (reported near $715–$745M), which monetizes or out?licenses assets while extending geographic reach for certain pain therapies—positive for pipeline monetization and incremental revenue potential. Pharmaceutical Executive Daily: AbbVie and Haisco Enter $745 Million Licensing Agreement
• Positive Sentiment: Early?stage ABBV?438 myeloma data continue to underscore AbbVie’s long?term oncology ambitions; successful advancement would broaden oncology exposure beyond established franchises. AbbVie’s ABBV-438 Myeloma Trial: Early-Stage Bet on Long-Term Oncology Growth
• Neutral Sentiment: AbbVie remains a dividend candidate for income investors and appears in recent roundups of high?yield healthcare names, which supports income?oriented demand even if growth questions persist. Wall Street’s Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
• Neutral Sentiment: Commentary on AbbVie’s progress in the weight?loss market highlights pipeline diversification but notes the company remains behind market leaders—an incremental positive but not an immediate revenue driver. Could AbbVie Crash Lilly’s Weight?Loss Party?
• Negative Sentiment: Evercore ISI slightly lowered its price target on ABBV (to $232 from $233) while keeping an Outperform rating—an incremental analyst headwind that can pressure intraday sentiment despite the small magnitude. Evercore ISI Tweaks AbbVie (ABBV) Estimates, Lowers Price Target Marginally

Insider Transactions at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Cantor Fitzgerald lowered their price objective on AbbVie from $250.00 to $240.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 8th. Morgan Stanley raised their price target on AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. The Goldman Sachs Group restated a “neutral” rating and issued a $223.00 price target on shares of AbbVie in a research report on Wednesday, January 28th. Finally, Berenberg Bank set a $275.00 price target on AbbVie in a research report on Tuesday, January 20th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $253.00.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $208.58 on Thursday. AbbVie Inc. has a 52 week low of $168.54 and a 52 week high of $244.81. The stock’s fifty day moving average is $219.49 and its 200 day moving average is $223.78. The stock has a market capitalization of $368.80 billion, a P/E ratio of 88.38, a PEG ratio of 0.75 and a beta of 0.38.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the previous year, the business posted $2.16 earnings per share. The business’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date is Wednesday, April 15th. AbbVie’s payout ratio is currently 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.